

# David Madigan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2276602/publications.pdf>

Version: 2024-02-01

41  
papers

2,974  
citations

257450

24  
h-index

302126

39  
g-index

43  
all docs

43  
docs citations

43  
times ranked

3990  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comprehensive Comparative Effectiveness and Safety of First-Line $\beta$ -Blocker Monotherapy in Hypertensive Patients. <i>Hypertension</i> , 2021, 77, 1528-1538.	2.7	20
2	Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers: A Multinational Cohort Study. <i>Hypertension</i> , 2021, 78, 591-603.	2.7	63
3	Large-scale evidence generation and evaluation across a network of databases (LEGEND): assessing validity using hypertension as a case study. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2020, 27, 1268-1277.	4.4	19
4	Principles of Large-scale Evidence Generation and Evaluation across a Network of Databases (LEGEND). <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2020, 27, 1331-1337.	4.4	31
5	Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis. <i>Scientific Reports</i> , 2020, 10, 11115.	3.3	23
6	Comparison of Cardiovascular and Safety Outcomes of Chlorthalidone vs Hydrochlorothiazide to Treat Hypertension. <i>JAMA Internal Medicine</i> , 2020, 180, 542.	5.1	97
7	How Confident Are We About Observational Findings in Health Care: A Benchmark Study. , 2020, 2, .		32
8	Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. <i>Lancet, The</i> , 2019, 394, 1816-1826.	13.7	228
9	Response to Marsh, G. M., Ierardi, A. M., Benson, S. M., & Finley, B. L. (2019). Occupational exposures to cosmetic talc and risk of mesothelioma: an updated pooled cohort and statistical power analysis with consideration of latency period. <i>Inhalation toxicology</i> , 31(6), 213â€“223. <i>Inhalation Toxicology</i> , 2019, 31, 385-386.	1.6	1
10	Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 2571-2577.	7.1	91
11	Bayesian hierarchical vector autoregressive models for patient-level predictive modeling. <i>PLoS ONE</i> , 2018, 13, e0208082.	2.5	5
12	Improving reproducibility by using high-throughput observational studies with empirical calibration. <i>Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences</i> , 2018, 376, 20170356.	3.4	53
13	Drospirenone-containing oral contraceptives and venous thromboembolism: an analysis of the FAERS database. <i>Open Access Journal of Contraception</i> , 2018, Volume 9, 29-32.	1.4	6
14	Streamlining cardiovascular clinical trials to improve efficiency and generalisability. <i>Heart</i> , 2017, 103, 1156-1162.	2.9	10
15	Causal Inference for Meta-Analysis and Multi-Level Data Structures, with Application to Randomized Studies of Vioxx. <i>Psychometrika</i> , 2017, 82, 459-474.	2.1	13
16	Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPORâ€ISPE Special Task Force on Real-World Evidence in Health Care Decision Making. <i>Value in Health</i> , 2017, 20, 1003-1008.	0.3	243
17	Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint <sc>ISPORâ€ISPE</sc> Special Task Force on real-world evidence in health care decision making. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1033-1039.	1.9	251
18	DUPLICATE: Recommendations for Good Procedural Practices for Real-World Data Studies of Treatment Effectiveness and/or Comparative Effectiveness Designed to Inform Health Care Decisions: Report of the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making. <i>Value in Health</i> , 2017, , .	0.3	1

#	ARTICLE	IF	CITATIONS
19	2402. Journal of Clinical and Translational Science, 2017, 1, 76-77.	0.6	0
20	Robust empirical calibration of $p$ -values using observational data. Statistics in Medicine, 2016, 35, 3883-3888.	1.6	43
21	Hierarchical models for multiple, rare outcomes using massive observational healthcare databases. Statistical Analysis and Data Mining, 2016, 9, 260-268.	2.8	11
22	Association Between Trauma Center Type and Mortality Among Injured Adolescent Patients. JAMA Pediatrics, 2016, 170, 780.	6.2	76
23	Characterizing treatment pathways at scale using the OHDSI network. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 7329-7336.	7.1	256
24	Predicting health outcomes from high-dimensional longitudinal health histories using relational random forests. Statistical Analysis and Data Mining, 2015, 8, 128-136.	2.8	7
25	Reassessing mechanism as a predictor of pediatric injury mortality. Journal of Surgical Research, 2015, 199, 641-646.	1.6	0
26	Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers. Studies in Health Technology and Informatics, 2015, 216, 574-8.	0.3	533
27	Sequential event prediction. Machine Learning, 2013, 93, 357-380.	5.4	31
28	Empirical Performance of a New User Cohort Method: Lessons for Developing a Risk Identification and Analysis System. Drug Safety, 2013, 36, 59-72.	3.2	57
29	A Comparison of the Empirical Performance of Methods for a Risk Identification System. Drug Safety, 2013, 36, 143-158.	3.2	71
30	Empirical Performance of the Case-Control Method: Lessons for Developing a Risk Identification and Analysis System. Drug Safety, 2013, 36, 73-82.	3.2	28
31	Does design matter? Systematic evaluation of the impact of analytical choices on effect estimates in observational studies. Therapeutic Advances in Drug Safety, 2013, 4, 53-62.	2.4	27
32	Massive Parallelization of Serial Inference Algorithms for a Complex Generalized Linear Model. ACM Transactions on Modeling and Computer Simulation, 2013, 23, 1-17.	0.8	113
33	Multiple Self-Controlled Case Series for Large-Scale Longitudinal Observational Databases. Biometrics, 2013, 69, 893-902.	1.4	35
34	Evaluating the Impact of Database Heterogeneity on Observational Study Results. American Journal of Epidemiology, 2013, 178, 645-651.	3.4	149
35	Learning From Epidemiology: Interpreting Observational Database Studies for the Effects of Medical Products. Statistics in Biopharmaceutical Research, 2013, 5, 170-179.	0.8	7
36	Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Statistics in Medicine, 2012, 31, 4401-4415.	1.6	154

#	ARTICLE	IF	CITATIONS
37	Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies. American Heart Journal, 2012, 164, 186-193.	2.7	22
38	Commentary: What Can We Really Learn From Observational Studies?. Epidemiology, 2011, 22, 629-631.	2.7	26
39	Persistence of Cardiovascular Risk After Rofecoxib Discontinuation. Archives of Internal Medicine, 2010, 170, 2035.	3.8	13
40	Large-scale regression-based pattern discovery: The example of screening the WHO global drug safety database. Statistical Analysis and Data Mining, 2010, 3, 197-208.	2.8	53
41	Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data. Archives of Internal Medicine, 2009, 169, 1976.	3.8	74